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It has previously been reported that human adipose-derived stem cells (hASCs) can promote the regeneration
of damaged tissues in rats with liver failure through a ‘paracrine effect’. Here we demonstrate a therapeutic
effect of hASCs derived Extracellular Vesicles (EVs) on rat models with acute liver failure, as shown by the im-
provement of the survival rate by N70% compared to controls. Gene sequencing of rat liver revealed an in-
crease in human long-chain non-coding RNA (lncRNA) H19 after hASC-derived EVs transplantation. When
the H19 coding sequence was silenced in hASCs and EVs were then collected for treatment of rats with
liver failure, we saw a decrease in the survival rate to 40%, compared to treatment with EVs generated from
non-silenced hASCs. These data indicate that lncRNA H19 may be a potential therapeutic target for the treat-
ment of liver failure.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Research in context
Our research shows a therapeutic effect of hASCs derived Extra-
cellular Vesicles (EVs) on rat models with acute liver failure, as
demonstrated by a survival rate improvement of N70%.We spec-
ulate that hASCs derived Extracellular Vesicles promote hepato-
cytes' proliferation and improve the survival of rats with acute
liver failure as a result of lncRNA H19 release.
1. Introduction
Liver failure poses a serious threat to the health of human beings.
Orthotopic liver transplantation is currently the most effective treat-
ment, but it is expensive and largely limited by the sources of the liver
donors, making it unsuitable to serve as a common treatment method
for the patients with end-stage liver failure ([1, 2]; Hessheimer et al.,
2017). It has been shown that stem cells can promote the regeneration
of impaired organs, tissues and cells through ‘cell replacement’ or the
‘paracrine effect’ ([4, 5, 53]; Jinglin et al., 2017; [7, 45]). As one of the
adult stem cells, human adipose-derived stem cells (hASCs) are charac-
terized by a high multiplication rate, broad differentiation potency and
relatively easy accessibility, for which they are expected to be ideal
seed cells for the treatment of some severe liver diseases such as acute
liver failure (ALF) [8–10].
Originally, researchers held the view that stem cells repaired tissue
injuriesmainly through ‘cell replacement’ [11–13]; however, recent an-
imal experiments have implicated that exogenous stem cells are largely
eliminated by the recipient's immune system after a short period of
time following in vivo transplantation, and very few stem cells differen-
tiated into the functional somatic cells at targeted organs, suggesting
that the therapeutic effect of transplanted stem cellsmay be attributable
to their paracrine capacity [14–16]. Our ﬁndings in acute liver failure rat
models show that hASCs facilitate the improvement of the rats' survival
rate and liver function recovery, but the hepatocyte-related protein is
not expressedwithin a short period of time after hASCs transplantation;
as such, it can be predicted that the main active mechanism of
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hASCs may result from the ‘paracrine effect’ rather than ‘cell replace-
ment’ [4, 53].
HASCs can secrete proteins and RNA in the form of Extracellular
Vesicles (EVs); the double-membrane structure of EVs can protect the
internal protein and RNA from being degraded by various extracellular
enzymes, and their functions can be exerted through interaction with
the target cell surface receptors [17–20]. It has been reported that EVs
isolated from BMSCs demonstrate better therapeutic effect in treating
some heart and renal diseases in animal models than stem cells by pro-
moting tissue repair and regeneration [21–28]. The efﬁcacy of stem cell-
derived EVs in treating acute liver injuries has also been reported
[29, 30], however, the detailed mechanism remains unclear. In this
study we obtained high-purity EVs from human adipose-derived stem
cells. These EVs were then transplanted via the iliac vein into rats with
acute liver failure, and a substantial therapeutic effect of hASCs-
derived EVswas observed.We further explored thepossiblemechanism
of hASCs-derived EVs in improving the outcomes of ratswith acute liver
failure throughwhole-genomeRNA sequencing and bioinformatic anal-
ysis. We identiﬁed lncRNA H19, which was released by hASC-EVs, as a
main target to exert the therapeutic effect by promoting hepatocytes'
proliferation and viability of the rats with acute liver failure.
2. Materials and Methods
2.1. Isolation and Identiﬁcation of hASCs
Adipose tissue was collected by liposuction from young healthy
donors, which was approved by the ethical committee of the People's
Liberation Army No. 85 Hospital, Shanghai, P.R. China (review serial
number NO.2013/18). Relevant informed consent forms were signed
by each donor before specimen collection. Adipose tissue was pulver-
ized and cut into small pieces of about 1 mm3 after being washed
three times in phosphate buffer solution (PBS) (Gibco, USA), and 0.1%
collagenase I (Gibco, USA) was added for 30-minute digestion. A com-
plete culture medium of an equal volume (DMEM-F12 culture medium
(Hyclone, USA), 10% fetal calf serum (Gibco, USA)) was added to termi-
nate digestion, and centrifugation was performed for 10min at a rate of
1000 rpm. PBS solution was used to re-suspend the cells, which were
then seeded into a T25 cell culture ﬂask at a density of 1 × 106/ml
after ﬁltration through a 40 μm cell strainer and placed into a 37 °C
and 5% CO2 constant temperature incubator (Thermo, USA) for culture.
Surface molecular markers of hASCs were detected by ﬂow cytome-
try as follows: hASCs of 2nd passagewere collected into 3 tubes of 500 μl
single-cell suspension, add 2 μl of anti-human CD44-FITC, CD90-FITC,
CD73-FITC, CD19-FITC, CD34-FITC, CD45-FITC and CD105-PE monoclo-
nal antibodies (eBioscience, USA) respectively, wash in PBS three
times after a 30-minute incubation at 37 °C and use a ﬂow cytometer
(caliber, BD, USA) for detection.
2.2. Adipogenic/Osteogenic/Chondrogenic Differentiation
The P2 generation hASCs were seeded into six-well plates at a den-
sity of 5 × 103/cm2 and cultured for three weeks in adipogenic/osteo-
genic/chondrogenic differentiation culture media. hASCs were washed
in PBS for three times, ﬁxed with 4% formalin for 10 min, incubated
for 30minwithOil RedO (Sigma, USA) or for 3 hwith Alizarin bordeaux
(Sigma, USA) or for 3 h with Alcian blue (HUXMA-90041; Cyagen Bio-
sciences Inc.) at room temperature, and observed under a microscope
after being washed in PBS for three times.
2.3. Isolation of hASCs-derived EVs
Culture medium of hASCs was collected and centrifuged at 3000 ×g
for 15 min to remove cells and cell debris. The supernatant was trans-
ferred to a sterile vessel and an appropriate volume of ExoQuick-TC
(System Biosciences, USA) was added to the bioﬂuid and mixed by
inverting or ﬂicking the tube. The sample was kept in refrigerate over-
night at 4 °C and centrifuged again at 1500g for 30 min next day. EVs
were spinned down by centrifugating at 1500g for 5 min. All the
supernant was discarded via aspiration. EV pellet was resuspended in
500 μl using PBS.
2.4. Characterization of hASCs-derived EVs
Firstly, we detected the physical shape of EVs using scanning elec-
tron microscope. One drop of hASCs-derived EVs (about 10 μg) was
added onto the sealing membrane and forceps were used to cover the
ﬂuid dropwith a carbon supportﬁlm copper grid forﬁve to tenminutes;
then one drop of 2% phosphotungstic acid staining solution was added
onto the sealing membrane and the copper grid was transferred from
the drop of hASCs-derived EVs to the drop of phosphotungstic acid;
after stained for three minutes, ﬁlter paper was used to absorb the liq-
uid, the hASCs-derived EVs were baked under a ﬁlament lamp and
observed with a transmission electron microscope.
The next, we detected the concentration and puriﬁcation of EVs
using Nanosight granulometer. The sample of hASCs-derived EVs was
prepared in 1 ml of solution of a proper concentration. A Nanosight
granulometer (NS300, UK) was used, the samples were injected into
the sample cell, the suspension of hASCs-derived EVs was irradiated
through the laser light source, the Brownian movement of the hASCs-
derived EVs was observed with scattered light and the particle size dis-
tribution information of the hASCs-derived EVs was obtained. Then
three-dimensional maps of the particle size were showed, correspond-
ing quantitative distribution intensity and scattering intensity.
Then we used the Antibody Chip Reagent Kit (System Bioscience,
USA) to test the surface markers of EVs. According to the instructions,
the, 500 μg of hASCs-derived EVs protein was added to 500 μl of lysate,
vortex mixing was performed for 15 s, 9 ml of EABB was added and
mixed up and down for three times. 10 ml of the above mixture was
added to the antibody chip and cultured overnight on a rocker at 4 °C.
The mixture was abandoned, 10 ml of washing solution was added
and kept stand on a rocker for 5 min at room temperature, the liquid
was abandon, 10 ml of antibody mixture was added to the chip and
kept stand on a rocker for 2 h at room temperature. The liquid was aspi-
rated from the chip using a sheet of dry aspiration paper after washed
for three times, mixed according to a 1:1 ratio so as to moderately de-
velop the color of the liquid drops on the chips, and photos were
taken under the chemiluminescence imaging system (LAS 4000 mini,
GE, Japan).
The protein concentration of the EVs could be determined using BCA
Protein Assay kit (Solarbio, Beijing, China). According to the instruc-
tions, the standard curve was plotted, the multi-gradient dilution of
the hASCs-derived EVs were performed and seeded into a 96-well
plate, 200 ml of BCA working solution was added to each well, the
plate was kept stand for 15 to 30 min at 37 °C, and a multi-functional
microplate reader (SoftMax Pro5, Molecular Devices, USA) was used
to determine the absorbance value at a wavelength of A562 nm. The
protein concentration was calculated according to the standard curve
and sample data. The protein concentration of the EVs used in the sub-
sequent tests was determined using this kit.
The amount of EVs could also be calculated by the expression of
CD63 protein on surface of EVs. According to the instructions of the
CD63 ELISA kit, 50 μl of protein standard and hASCs-derived EVs were
added to a 96-well plate, and incubation was perform for two hours at
37 °C. After washed three times in a washing solution, 50 μl of EVs pri-
mary antibody was added and kept stand on a rocker for 1 h at room
temperature. After washed three times in a washing solution again,
50 μl of EVs secondary antibody was added and kept stand on a rocker
for 1 h at room temperature. After a third round of washing three
times in a washing solution, 50 μl of TMB substrate was added and
kept stand on a rocker for 30 min at room temperature; then 50 μl of
stop buffer was added and the absorbance was detected using a multi-
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functional microplate reader when the color in the well turns from blue
to yellow.
To test if EVs could be uptaken by hepatocytes in vitro, we labelled
the protein and RNAs in EVs and co-cultured the EVs with hepatocytes.
In 500 μl of 1 μg/μl hASCs-derived EVs, the carboxyﬂuorescein
succinimidyl diacetate ester (CFSE) and acridine orange were added in
the 500 μl ﬂuorescent labelling reagent kit (System Bioscience, USA).
The well was mixed and kept stand for 10min at 37 °C, ExoQuick anti-
bodywas added to terminate the ﬂuorescence labeling, reversed upside
down for six times and kept stand on ice for 30 min. Centrifuged at a
rate of 14,000 rpm for 3 min, the supernatant was removed and 500 μl
of PBS was added for dilution. The labeled EVs (100 μl per well) were
added to the HL-7702 cells (human hepatocytes, Shanghai Linjiang Bio-
technology Co., Ltd.) in the six-well plate and incubated for two hours.
Then the uptake of the EVs by hepatocytes was observed under a ﬂuo-
rescent microscope.
2.5. Use of hASCs-derived EVs to Treat D-gal Induced ALF
Firstly, we established animal models with acute liver failure. Proce-
dures involving animals and their care were conducted in conformity
with animal ARRIVE guidelines and was approved by Animal Care and
Use Committee of the Tongji University. 60 healthy male Sprague
Dawley (SD) rats (130–150 g, grade:SPF, license: SCXK 2013-0005,
SLAC Laboratory Animal Co., Ltd. (Shanghai, China)) at the age of 4–6
weeks were enrolled. The acute liver failure models were established
by the two-time intraperitoneal injection of 0.8 g/kg D-aminogalactose
with a 12-hour interval.
At 24 h after the establishment of acute liver failure rats models, the
60 rats were randomly divided into six groups: the group in which the
rats received low-concentration of hASCs-derived EVs (20 μg/rat) via
trans-iliac venous transplantation, the group in which the rats received
high-concentration of hASCs-derived EVs (100 μg/rat), the group in
which the rats received low-concentration of lysate (20 μg/rat), the
group in which the rats received high-concentration of lysate (100 μg/
rat), the hASCs (2 × 106 cells/rat) treated group and the PBS group as
the control, and observe the 72-hour overall survival rate.
To observe the histopathological changes in rat's liver tissues, speci-
mens from the peripheral sites of the hepatic portal vein were collected
and embed in parafﬁn according to the conventional procedures, HE
staining was performed and the hepatic histological manifestations
was observed under a light microscope.
2.6. RNA sequencing analysis of rats' liver tissues
The rats' liver tissues were collected in the high-concentration
hASCs-derived EVs transplantation group and PBS control group, TRIzol
reagent was added to extract the RNA of the liver tissue, the total quan-
tity wasmeasured using an RNA quantitative device and preserved it in
a− 80 °C refrigerator; a cDNAbankwas established for the RNAwith an
RIN value of N8.0 as measured, the RNA sequence was detected on a
ProtonTm system platform using the high-ﬂux sequencing method
and a corresponding RNA sequence heatmapwas shown. Themeasured
RNA sequenceswere comparedwith the human and rat RNAbanks, and
the differences between these two groups were found in terms of
human and rat's RNA expression.
To analysis these signal pathways, all detected RNA sequences were
retrieved in the KEGG database in the form of FASTA (http://
geneontology.org/), important signal pathways were selected by
means of the FISHER exact test and the P value was corrected using
the Benjamini-Hochberg method; the signiﬁcance is only considered
in case P b 0.05 and in the presence of functional gene categories and
pathways.
To analysis the role of signal pathways in the network, the important
signal pathways of the bodies involved in all RNAswere prepared as de-
tected in the netgraphs, the selected genes were genes with abundant
content in the pathways (P b 0.05) and the position of each signal path-
way in the network and their mutual relationships were observed.
Then we use RT-qPCR for in vitro validation, the hASCs-derived EVs
were lysed using TRIzol and the expression of the drug metabolism sig-
nal pathway related genes were detected using RT-qPCR.
2.7. Role of lncRNA H19 in hASCs-derived EVs
To verify the role of H19 in EVs, we collected the hASCs-derived EVs
with silenced lncRNA H19. The H19 shRNA (Accession number: 5′-3′
GCAAGAAGCGGGTCTGTTTCT)-carrying plasmid pGLV3/H1/GFP +
Puro Vector was constructed, packed in the lentivirus and used to infect
the hASCs, the hASCs with silenced H19 genes were harvested and the
EVs were collected. RT-qPCR was used to detect the expression of
lncRNA H19 in hASCs-derived EVs before and after silencing.
The next, In vitro proliferation test of human hepatocytes (HL-
7702) was performed when co-cultured with EVs, human hepatocytes
were seeded in a 96-well plate at the rate of 5000 cells/well; after the
cells became adherent, the hASCs-derived EVs and hASCs-derived EVs
with silenced H19 genes were added to the blank plates according to
different concentrations, CCK8 reagent was added at the rate of 10 μl
at different time points and incubated for 30 min; then the A450
value was detected and the respective impact of the two groups of
hASCs-derived EVs on the proliferation of human hepatocytes were
evaluated.
Then we transplanted the hASCs-derived EVs of the silenced H19
gene and observed the 72-hour overall survival rate. 30 healthy male
SD rats (130–150 g, grade:SPF, license: SCXK 2013–0005, SLAC Labora-
tory Animal Co., Ltd. (Shanghai, China)) at the age of 4–6 weeks were
enrolled. All animal ARRIVE guidelines have been met. The acute liver
failure models were established by the two-time intraperitoneal injec-
tion of 0.8 g/kg D-aminogalactose with a 12-hour interval. At 24 h
after the model establishment, the rats were randomly divided into
three groups: the group in which the rats received hASCs-derived EVs
(100 μg/rat) via the trans-iliac venous transplantation, the group in
which the rats received the hASCs-derived EVs of the silenced H19
gene (100 μg/rat) and the PBS control group, and the 72-hour overall
survival rate was observed.
2.8. Use of hASCs-derived EVs to Treat D-gal + LPS Induced ALF
We further established amore severe ALFmodelwithD-gal + LPS to
observe the inﬂammatory status in rats when treating with EVs. 21
healthy male SD rats (130–150 g, grade:SPF, license: SCXK 2013-0005,
SLAC Laboratory Animal Co., Ltd. (Shanghai, China)) at the age of 4–6
weeks were enrolled. All animal ARRIVE guidelines have been met.
The acute liver failuremodels were established by intraperitoneal injec-
tion of 0.8 g/kg D-aminogalactose and 5 μg/kg LPS.
At 2 h after the establishment of the acute liver failure rate models,
the 21 rats were divided into two groups: the group in which the rats
received high-concentration hASCs-derived EVs (100 μg/rat) (10 rats)
via trans-iliac venous transplantation and the group in which the rats
received PBS (11 rats), and the 72-hour overall survival rate and histo-
pathological changes in rat's livers tissues was observed.
To detect rats' liver function indicators, the rat's serumwas collected
1 day after the transplantation and a blood biochemical analyzer was
used to detect the concentrations of ALT, AST and LDH in the rat serum.
We also collected rat's serum for protein chip detection, at 1 day
after the transplantation, a qualitative analysis of the expression of
such inﬂammatory factors as IL-1ra, IL-1α and IL-1β, and such chemo-
tactic factors as CCL3, CCL5 and CCL20 was made, in the rat serum
using the rat cytokine protein chip method (R&D, ARY008). Photos
were taken using a gel imaging system (GE, LAS4000 mini) and the
Mean Pixel Density was analyzed using HLImage software.
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2.9. Underlying Mechanism of lncRNA H19 on Hepatocytes
From the RNA sequencing analysis above, we also found an up-
regulation of HGF/c-Met pathway. So, RT-qPCRwas use to verify the ex-
pression of HGF and c-Met in rats' liver before and after transplantation
of high-concentration hASCs-derived EVs.
To verify the role of H19 in EVs, we collected the hASCs-derived EVs
with overexpressed lncRNA H19. The H19-carrying plasmid GV461
(CMV-betaGlobin-MCS-SV40 PolyA) Vector was constructed, packed
in the adenovirus (AAV) and used to infect the hASCs, the hASCs with
overexpressed H19 genes were harvested and the EVs were collected.
RT-qPCR was used to detect the expression of lncRNA H19 in hASCs-
derived EVs before and after overexpressing.
Then, we detected hepatocytes' proliferation with the CCK8 kit. The
cells were divided into four groups: H19-EVs, AZD6094-EVs, EVs and
control. The hepatocytes were inoculated in a 96-well plate with a cell
density of 2000 cells/well. 24 h later, 8 mg/ml D-gal and 0.05 μg/ml
LPS were added into the culture medium; for the AZD6094-EVs group,
an additional 0.8 mg/ml of c-Met kinase inhibitor AZD6094 (AZD6094
is a type of ATP-competitive c-Met inhibitor whichmay block the signal
transduction of the HGF/c-Met pathway) was added. 24 h later, 1 μg/ml
of hASCs-derived EVs with an overexpression of H19, hASCs-derived
EVs, hASCs-derived EVs and PBSwere added to the groups respectively.
CCK8 reagent was added at 2 h, 24 h, 48 h, 72 h, and 96 h and incubated
at 37 °C for 1 h and theODat awavelength of 450 nmwasdetectedwith
a multi-function microplate reader.
The next, we detected hepatocytes' apoptosis with the TUNEL kit,
the cells were divided as above, cultured at 37 °C for 24 h and ﬁxed
for 30 min in 4% paraformaldehyde and implement PBS cleaning.
Then the primary antibodies and secondary antibodies were sealed
and incubated, DAPI was added and sealed the slides. Finally, the he-
patocyte apoptosis was observed under an upright ﬂuorescence
microscope.
We also detected hepatocytes' apoptosis with ﬂow cytometry, the
cells were divided as above, cultured at 37 °C for 24 h and digested for
3 min in 0.25% trypsin. To prepare single-cell suspension, 100 μl of sus-
pensionwas taken, 3 μl of AnnexinV-FITC and PIwere added and placed
at room temperature for 30 min, The appropriate amount of 1× buffer
was added and ﬁnally apoptosis conditions were detected with a ﬂow
cytometer.
Again, animal models with acute liver failure were established, 30
healthy male SD rats (130–150 g, grade:SPF, license: SCXK 2013–0005,
SLAC Laboratory Animal Co., Ltd. (Shanghai, China)) at the age of 4–6
weeks were enrolled. All animal ARRIVE guidelines have been met.
The acute liver failuremodels were established by intraperitoneal injec-
tion of 0.8 g/kg D-aminogalactose and 5 μg/kg LPS.
At 2 h after the establishment of the acute liver failure rate models,
the 40 rats were divided into four groups: the group in which the rats
received hASCs-derived EVs with an overexpression of H19 (100
μg/rat) (10 rats) via trans-iliac venous transplantation, the group in
which the rats received hASCs-derived EVs (10 rats), the group in
which the rats pretreated with AZD6094 and received hASCs-derived
EVs (10 rats) and the group in which the rats received PBS (10 rats),
and the 72-hour overall survival rate was observed.
Then, Ki67 immunohistochemical staining of was performed to ver-
ify the regeneration of rat's liver tissues. Parafﬁn imbeddingwas carried
out for the hepatic tissue, then sliced and deparafﬁnated the tissue,
repaired the antigen and incubated the primary and secondary antibod-
ies. DAB coloration, transparency, slice sealing and conventional immu-
nohistochemical treatment were conducted. The hepatic proliferation
was observed under a microscope.
Correspondingly, hepatic apoptosis was detected using the TUNEL
kit. Parafﬁn imbeddingwas carried out for the hepatic tissue, then sliced
and deparafﬁnated the tissue, repaired the antigen, sealed and incu-
bated the primary and secondary antibodies. Later, DAPI, slice sealing
and conventional immunohistochemical treatment were conducted.
Finally, the hepatic apoptosis was observed under an upright ﬂuores-
cence microscope.
Finally, we detected the expression of HGF, c-Met, STAT3 and PI3K of
hepatic tissue using RT-qPCR. Hepatic tissues were taken from rats in
each group, RNAs were extracted with TRIzol, cDNA was formed
through reverse transcription and the gene expression quantity of
HGF, c-Met, STAT3 and PI3K were detected through real-time ﬂuores-
cence quantiﬁcation PCR.
2.10. Statistical Data and Analysis
The experimental datawas statistically analyzed using the SPSS 19.0,
and the indicators of the measurement data were expressed using the
mean ± standard error (X ± SEM). The Kaplan-Meier method was
adopted for the survival analysis, with P b 0.05 meaning a statistically
signiﬁcant difference.
3. Results
3.1. Isolation and Identiﬁcation of hASCs
The hASCs was cultured up to ﬁve passages as previously reportedly
[4, 53]. The hASCs showed typical spindle-like structures without obvi-
ous changes in shape, size or density (Fig. S1A). These hASCs had a high
percentage of positive expression of mesenchymal stem cells markers
such as CD73 (100%), CD44 (100%), CD90 (99.9%), CD105 (97.2%), etc.
and nearly no expression of hematopoietic cell line molecular markers
such as CD34, CD45 and CD19 (0.8%) by the ﬂow cytometry (Fig. S1B).
Three-lineage differentiation assay was performed to test the multiple
potency of hASCs. After culturing for threeweeks on agarmedium,mas-
sive amounts of lucent lipid droplets of a high refractivity could be visu-
alized in the cytoplasm as observed under a microscope, and the color
red was developed after using Oil Red O for staining; after a three-
week osteogenic/chondrogenic medium culture, the cells were stained
using Alizarin bordeaux/Alcian blue and the majority of the cells were
stained red/blue as observed under the microscope (Fig. S1C). These
results indicated that we obtained hASCs with high purity and multi-
differentiational ability.
3.2. Characterization of hASCs-derived EVs
hASCs-derived EVs were isolated using ExoQuick-TC kit and EVs
were characterized by a scanning electron microscope (SEM) and a
Nanosight granulometer. Under SEM, the hASCs-derived EVs could be
visualized with saucer-like or concave-hemispheric structures and rela-
tively similar sizes ranged from about 30 to 150 nm (Fig. 1A). When
using a Nanosight granulometer to detect the hASCs-derived EVs, the
dimension/concentration curve showed that the hASCs-derived EVs
had dimensions of about 30 to 150 nm with a mean of about 100 nm,
and the sample concentration was 4 × 107 particles per ml. As shown
in the dimension/intensity curve, the hASCs-derived EVs had an inten-
sity of about 0.5 to 6 a.u., and the particles with dimensions of about
150 nm had the highest intensity. As shown in the dimension/concen-
tration/intensity three-dimensional graphics, the hASCs-derived EVs
had a relatively high purity within the dimension range of 80 to 120
nm. In addition, the Brownian movement of the hASCs-derived EVs in
the ﬂuid could be captured by means of a granulometer (Fig. 1B). Sur-
face markers of hASCs-derived EVs were detected by protein chip as-
says. The majority of protein markers for EVs including CD81, ANXA5,
ICAM, ALIX, TSG101, FLOT1, CD63 and GM130were detectible (Fig. 1C).
The factors which might affect the yield of hASCs-derived EVs were
analyzed by a Nanosight granulometer and the ELISA assay. The protein
concentration of the collected hASCs-derived EVs was positively corre-
lated with the quantity of EVs (Fig. 1D). These results indicated that
the conﬂuence of hASCs culture, cell generation (within the fourth gen-
eration), cell quality (visual measurementmethod) and times of culture
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medium collection (within two times) were positively correlated with
the protein concentration of the EVs (BCA Protein Assay method)
(Fig. 1E).
To test whether the EVs could be uptaken by hepatocytes, hASCs-
derived EVs were labelled by GFP and RFP for EV-speciﬁc protein and
RNA respectively. Then hASCs-derived EVs were incubated with hepa-
tocytes for two hours. GFP and RFP-positive particles could be simulta-
neously visualized within the hepatocellular cytoplasm (Fig. 1F), and
both green and red ﬂuorescence didn't become dimmer over time, im-
plying that hASCs-derived EVs could penetrate hepatocellular mem-
branes, enter hepatocellular cytoplasm and exist in hepatocytes for a
relatively long period of time.
3.3. hASCs-derived EVs Can Signiﬁcantly Rescue D-galactosamine (D-gal)
Induced Acute Liver Failure (ALF)
As previously reported, hASCs can partially rescue the ALF. We fur-
ther explored whether the effect of hASCs on ALF is mainly achieved
through EVs. The ALF rat model was made by the intraperitoneal
injection of D-gal. One day after establishing the ALF disease model,
the rats received an injection of low-concentration hASCs-derived EVs
(20 μg/rat), high-concentration hASCs-derived EVs (100 μg/rat),
low-concentration lysate (20 μg/rat), high-concentration lysate (100
μg/rat), hASCs (2 × 106 cells/rat) and PBS via the iliac vein, and the over-
all survival rates were 62.5%, 100%, 25%, 50%, 37.5% and 27.3%
respectively. When comparisons were made between the high and
low-concentration EVs transplantation groups and the control group,
the survival rates at different time points presented signiﬁcant differ-
ences (P b 0.05) (Fig. 2A). These results indicated that hASCs-derived
EVs can rescue the ALF and this therapeutic effect is relative to their
concentration.
To observe the histology change of rat's liver, HE staining was per-
formed on the hepatic tissues at 24 h after transplantation. As ob-
served under an optical microscope, a large area of degeneration and
necrosis could be visualized in rats' liver in the high and low-
concentration hASCs lysate transplantation groups, the hepatic sinus
became dilated and massive inﬂammatory cell inﬁltration could be vi-
sualized in the portal area and necrotic area; as for the rats in the
Fig. 1. Identiﬁcation of hASCs-derived EVs. (A) Observation under electron microscope: the hASCs-derived EVs appeared globular with a size ranging from about 30 to 150 nm. (B) The
physical parameters of the hASCs-derived EVs were detected using the Nanosight granulometer, the curve described the relationship between particle size (X axis) and concentration/
intensity distribution (Y axis), and it was visible that the size of most hASCs-derived EVs ranged from 30 to 150 nm; the Brownian movement of the hASCs-derived EVs in liquid could
be visualized. (C) The common surface protein markers of the hASCs-derived EVs were detected by the protein chip method, and ImageJ software was used to calculate the mean grey
level. (D) Detection was performed using a Nanosight granulometer and the ELISA method, and the protein content of the collected hASCs-derived EVs was positively correlated with
the quantity of EVs. (E) The hASCs fusion degree, cell generation, cell quality and times of culture medium collection was positively correlated with the protein content of the EVs (BCA
protein determinationmethod). (F) Red or greenﬂuorescencewas displayed after the hepatocellular uptake of the EVs under a ﬂuorescencemicroscope, indicating the presence of RNA or
proteins in the EVs. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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high-concentration hASCs-derived EVs transplantation group, the he-
patic structures of their hepatic lobules and hepatic sinus basically re-
covered to normal, with only a small amount of inﬁltrated
inﬂammatory cells detectible. (Fig. 2B). These results indicated that
the transplantation of hASCs-derived EVs reduced the necrosis and in-
ﬂammation in rats' liver.
3.4. The Main Signaling Pathway, Which May Have Impact on the Thera-
peutic Effect of hASCs-derived EVs is Unraveled by Whole-genomic
Sequencing and Bioinformatic Analysis
To explore the mechanism of hASCs-derived EVs in rescuing rats
with ALF, the RNA of rats' hepatic tissues in the high-concentration
Fig. 2.hASCs-derived EVs rescueD-gal inducedALF. (A) The72-hour survival rates of high-concentration and low-concentration hASCs-derived EVs transplantation groups (‘EVs-high’ and
‘EVs-low’), high-concentration and low-concentration hASCs lysate transplantation group (‘Lys-high’ and ‘Lys-low’), hASCs transplantation group and PBS control groupwas observed. The
comparison between the EVs-high and EVs-low groups and the control group showed signiﬁcant differences in terms of survival rates at different time points (P b 0.05). (B) The parafﬁn
sections of the liver tissues of rats in each groupwere prepared, and photos taken under a microscope after HE staining (400×). (C) The liver tissues of the rats in the EVs-high group and
the control groupwere collected and homogenized, then second-generation gene sequencingwas performed to create a heatmap. (D) The KEGG signal pathway analysis of the sequencing
results showed that, when compared with the control group, there was an up-regulation in pathways such as coagulation cascades, drugmetabolism andMAPK Signaling in the EVs-high
group. (E) There was a down-regulation in pathways such as inﬂammatory mediator regulation of the TRP channels and chemokine signaling pathway. (F) Through signal network
analysis, after high-concentration hASCs-derived EVs treatment, such up-regulated signal pathways as complement, hemagglutination, drug metabolism and MAPK signaling were at
the core positions in the entire signal pathway network (red represents up-regulated genes and green represents down-regulated genes). (G) The related enzymes involved in drug
and poison metabolism in the drug metabolic pathway were clearly up-regulated. (H) The results of RT-qPCR detection re-validated the sequencing results. (For interpretation of the
references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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hASCs-derived EV transplantation group and control group was
sequenced simultaneously. From the heatmap, it was clearly evident
that the injection of high-concentration hASCs-derived EVs could
impact the RNA expression of rat' liver tissues when compared with
the control group (Fig. 2C). After conducting a KEGG signal pathway
analysis of the sequencing results, it was noted that when compared
with the control group, after the injection of the high-concentration
hASCs-derived EVs, some important intrahepatic signal pathways
which are essential for maintaining the normal liver function, such as
coagulation cascades, drug metabolism and MAPK signaling were
up-regulated (Fig. 2D). Nonetheless, some signaling pathways which
may affect the inﬂammatory status of the liver, such as the inﬂamma-
tory mediator regulation of the TRP Channels and chemokine signaling
pathway became down-regulated (Fig. 2E). The network of the main
signaling pathways was further analyzed by Pathway-Act-Network
analysis. Consistent with KEGG signal pathway analysis, the rats in the
high-concentration EVs transplantation group also showed the signiﬁ-
cant up-regulation of such signal pathway-related genes as coagulation
cascades, drugmetabolism andMAPK Signaling, whichwere at the core
position in the entire signal pathway network (Fig. 2F). The related
enzymes involved in drug and poison metabolism, such as Cyp2c13,
Hsd11b1, Ugt2b15 et al., were clearly up-regulated (Fig. 2G) and the
RT-qPCR results re-validated the sequencing results (Fig. 2H).
3.5. Role of lncRNA H19 in hASCs-derived EVs
After a comparison between the RNA sequencing results and human
and rat gene banks, an up-regulation was found in the human-derived
long-chain non-coding RNA H19 gene measured in the hepatic tissues
of rats in the hASCs-derived EVs group. Software was used to predict
the microRNA that might interact with human lncRNA H19, and it was
found that lncRNA H19 happened to be closely associated with the
microRNA of coagulation functions, drug metabolism, etc. pathways.
We also found in the previous RNA sequencing results that there was
an up-regulation in genes related to the coagulation function and drug
metabolic pathways in rat hepatic tissues. As such, it was assumed
that hASCs-derived EVs are very likely to inhibit the expression of
microRNA related to the coagulation function, drug metabolism, etc.
pathways in rats, thus up-regulating such pathways and improving
the survival rate of rats with ALF (Fig. 3A).
To explore the role of lncRNAH19 in hASCs-derived EVs,we silenced
H19 genes in hASCs and collected the EVs for in vitro and in vivo
Fig. 3. Functionof lncRNAH19onhepatocytes. (A)Aftera comparisonbetween theRNAsequencing results andhumanandrat genebanks, itwas foundthat therewasanup-regulation in the
human-derived long-chainnon-codingRNAH19genemeasured in thehepatic tissuesof the rats in thehASCs-derivedEVs group. (B)Theexpressionof lncRNAH19 in thehASCs-derivedEVs
became clearly down-regulated after theH19 genewas silenced. (C) hASCs-derived EVswith silencedH19 genes had no promotional effects on theproliferation of hepatocytes. (D) The rats
in the hASCs-derived EVs group and hASCs-derived EVs with silenced H19 gene group presented signiﬁcant differences in terms of their survival rates at different time points (P b 0.05).
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experiment. RT-qPCR was used to detect the expression of lncRNA H19
in hASCs-derived EVs before and after silencing. As shown in RT-qPCR
detection, the expression of lncRNA H19 in hASCs-derived EVs became
clearly down-regulated after the H19 gene was silenced (Fig. 3B).
In vitro experiment, we co-cultured the EVs and hepatocytes, as
shown in CCK8 detection, hASCs-derived EVs can promote human
hepatocellular proliferation, nevertheless, hASCs-derived EVs with
silenced H19 genes lost their promotional effects which indicated that
H19 may be crucial in the promotion process of hepatocellular prolifer-
ation (Fig. 3C).
In vivo experiment, we also observed the 72-hour overall survival
rate of rats treating with hASCs-derived EVs with silenced H19 genes.
At 1 day after model establishment through the intraperitoneal injec-
tion of D-gal, rats receiving the injection of hASCs-derived EVs (100
μg/rat), hASCs-derived EVs with the silenced H19 gene (100 μg/rat)
and PBS via the iliac vein had 72-hour overall survival rates of 100%,
40% and 10% respectively. The rats' survival rates in the hASCs-derived
EVs group and the hASCs-derived EVs with silenced H19 gene group
presented signiﬁcant differences at different time points (P b 0.05)
(Fig. 3D). These results indicated that H19 may be crucial in promoting
hepatocellular proliferation and thus rescuing rats with ALF.
3.6. hASCs-derived EVs Rescue D-gal + Lipopolysaccharide (LPS) Induced
ALF
From the experiments above, we found that hASCs-derived EVs
could promote hepatocellular proliferation and rescue rats with D-gal
induced ALF. To further verify the therapeutic effect of EVs, we
established a more severe and fatal model of ALF using D-gal and LPS.
At 2 h after model establishment through the intraperitoneal injection
of D-gal + LPS, the rats received an injection of high-concentration
hASCs-derived EVs (100 μg/rat) and PBS via the iliac vein, and the 72-
hour overall survival rates were 50% and 9% respectively; the rats in
the two groups presented signiﬁcant differences in terms of the survival
rates at different time points (P b 0.05) indicating that hASCs-derived
EVs also had therapeutic effect in D-gal + LPS induced ALF (Fig. 4A).
Histology examination showed that the rats in the PBS control group
had damaged hepatic lobule structures, dilated hepatic sinuses with
congestion and bleeding, and massive inﬂammatory cell inﬁltration
could be visualized in the portal area and necrotic area; as for the rats
in the hASCs-derived EVs transplantation group, the structures of their
hepatic lobules and hepatic sinuses basically recovered to normal,
with only a small amount of inﬂammatory cell inﬁltration visible
which indicated that hASCs-derived EVsmay improve the inﬂammatory
status in rats' liver (Fig. 4B).
Also, the level of Alanine aminotransferase (ALT), Aspartate amino-
transferase (AST) and Lactate Dehydrogenase (LDH) in rats' serum
were detected for evaluation of rats' liver function. At 24 h after trans-
plantation, the rats in the hASCs-derived EVs transplantation group
had a signiﬁcantly lower level of ALT [(7091.4 ± 3473.9) U/L] than
those in the control group [(10,615 ± 2950.8) U/L], lower level of AST
[(7627.5 ± 3822.5) U/L] than those in the control group [(16,163.8 ±
4660.6) U/L]; and lower level of LDH [(62,476.3 ± 32,829.8) U/L] than
those in the control group [(83,902.5 ± 17,114.3) U/L] (P b 0.05)
(Fig. 4C). These results indicated that hASCs-derived EVs contributed
to the recovery of rats' liver function.
To clearly investigate the inﬂammatory status in rats' liver, we har-
vested rat serum for protein chip detection. At 1 day after transplanta-
tion, the rats in the hASCs-derived EVs transplantation group had a
lower level of such inﬂammatory factors in the rat serum as IL-1ra,
IL-1α, IL-1β, IL-6 and IL-17 than those in the PBS control group; and a
lower level of such chemotactic factors as CCL20, CINC-1, CINC-2α/β,
CINC-3, CNTF, CX3CL1, CXCL7, CXCL9, CXCL10 and LECAM-1 than
those in the PBS control group indicating that hASCs-derived EVs also
have some anti-inﬂammatory effect (Fig. 4D).
3.7. UnderlyingMechanism of lncRNAH19 in Treating D-gal + LPS Induced
ALF
From the RNA sequencing analysis above, we also found an
up-regulation of HGF/c-Met pathway and this was veriﬁed in the liver
tissue of rats using RT-qPCR method (Fig. S2A). HGF/c-Met pathway is
a well-known pathway associated to cells proliferation. To explore the
role of HGF/c-Met pathway in rats treating with EVs, we constructed
the adenovirus (AAV) overexpressingH19, infected hASCs and collected
their EVs. RT-qPCR was used to detect the expression of lncRNA H19 in
hASCs-derived EVs before and after overexpressing. As shown in
RT-qPCR detection, the expression of lncRNA H19 in hASCs-derived
EVs became clearly up-regulated after the H19 gene was overexpressed
(Fig. S2B). In vitro experiment, we found that hASCs EVs with an over-
expression of H19 (H19-EVs) promoted hepatocytes' proliferation,
which hints that H19 can further enhance the role of hASCs-derived
EVs in promoting hepatocytes' proliferation. Then the c-met inhibitor—
AZD6094 was used to block HGF/c-Met pathway in hepatocytes. After
pretreatmentwith AZD6094, hASCs-derived EVs lost their effect on pro-
moting hepatocytes' proliferation, which indicated that hASCs-derived
EVs may promote hepatocytes' proliferation through the HGF/c-Met
pathway (Fig. S3A).
We also found that lncRNA H19 reduced hepatocytes' apoptosis
in vitro. The apoptosis rate of the H19-EVs group is lower than that of
the EVs group, which indicates that H19 can enhance the protective
effect of EVs on hepatocytes, thus reducing drug-induced hepatocytes'
apoptosis. The apoptosis rate of the AZD6094-EVs group is higher than
that of the EVs group, which indicates that hASCs-derived EVs may
reduce hepatocytes' apoptosis through the HGF/c-Met pathway
(Fig. S3B). H19-EVs, EVs, AZD6094-EVs and control groups had late
apoptosis rates of 10.6%, 12.1%, 24.8% and 26.5% respectively. The apo-
ptosis rate of H19-EVs is lower than those of the other three groups,
which indicated that H19 can reduce the toxic effects of D-gal and LPS
on hepatocytes, thus improving the role of EVs in apoptosis inhibition
(Fig. S3C).
In vivo experiment, hASCs-derived EVs promoted hepatocytes' pro-
liferation in damaged liver tissues, and H19 further enhanced the role
of EVs in promoting hepatocytes' proliferation. The number of brown
nuclei in the AZD6094 intervention group was slightly lower than that
of the hASCs-derived EVs group, which indicated that hASCs-derived
EVs may promote the regeneration of rats' liver through the HGF/c-
Met pathway (Fig. S3D, F).
Then we detected the hepatic apoptosis in the hepatic tissues of rats
with the TUNEL kit and found that lncRNAH19 reduced the apoptosis of
rats' liver. The number of apoptotic cells of the H19-EVs group is signif-
icantly lower than that of the hASCs-derived EVs, AZD6094-EVs and
control groups, which indicated that hASCs-derived EVs could reduce
the damage of hepatic tissues caused by D-gal + LPS, and H19 can en-
hance the protective effects of EVs on hepatocytes. The apoptosis degree
of the AZD6094-EVs group is greater than that of the hASCs-derived EVs
group, which indicated that EVs may protect hepatocytes and reduce
the apoptosis of rats' liver through the HGF/c-Met pathway (Fig. S3E, F).
The 72-hour overall survival rates of the H19-EVs, AZD6094-EVs,
EVs and control groups were 80%, 20%, 50% and 10% respectively; the
rats in theH19-EVs and control groups presented signiﬁcant differences
in terms of their survival rates at different time points, while the rats in
the AZD6094-EVs and EVs groups likewise presented signiﬁcant differ-
ences in terms of their survival rates at different time points (Fig. S3G).
To explore the mechanism of H19 in inﬂuencing HGF/c-Met path-
way, we detected the gene expression quantity of HGF, c-Met, STAT3
and PI3K of hepatic tissue using RT-qPCR. The gene expressive quantity
of HGF, STAT3, and PI3K in the liver tissues of the rats in the AZD6094-
EVs group were lower than those in H19-EVs and EVs groups, which
indicated that hASCs-derived EVs could promote hepatocytes' prolifera-
tion through up-regulating the expressions of HGF, STAT3, and PI3K.
However, the expressions of HGF, STAT3 and PI3K are all restrained
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after treatment with AZD6094, and the AZD6094-EVs group has the
lowest expression quantity of c-Met, which may be caused by the role
of AZD6094 in restraining c-Met (Fig. S3H).
4. Discussion
Over the recent years, some researchers considered that stem cells
used in cell therapy may trigger the body's rejection reaction and
cause embolization, even death. While extracellular vesicles, a kind of
particle in nanoscale containing a rich variety of proteins and nucleic
acids, are apparently easier to be transported and perform their func-
tions without the potential risk of embolism, and have a better perfor-
mance in safety compared with stem cells by minimizing the potential
risk to trigger innate and adaptive immune response.Moreover, the col-
lected extracellular vesicles are also easier to preserve without losing
their activities.
Fig. 4. hASCs-derived EVs rescue D-gal + LPS induced ALF. (A) When a comparison was made between the high-concentration EVs transplantation group and control group, the survival
rates at different time points presented signiﬁcant differences (P b 0.05). (B) At 24 h after the transplantation, the parafﬁn sections of the liver tissues of rats in each groupwere prepared,
and photos were taken under a microscope after HE staining (400×). (C) At 24 h after transplantation, the rats in the high-concentration hASCs-derived EVs transplantation group had a
signiﬁcantly higher level of ALT, AST and LDH than those in the control group (P b 0.05). (D) Aswas shown in the protein chip detection, at 1 day after transplantation, the rats in the high-
concentrationhASCs-derived EVs transplantation grouphad a signiﬁcantly lower level of inﬂammatory factors in the rat serum than those in the PBS control group, aswell as a signiﬁcantly
lower level of chemotactic factors than those in the PBS control group.
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Stem cells-derived EVs can be involved in immunoregulation, pro-
motion of vasculogenesis and impaired tissue's proliferation, reduction
of inﬂammatory reactions and apoptosis etc. [31–37] through carrying
a large amount of packaged proteins and RNAs. Due to EVs' intrinsic
targeting characteristics, cargo proteins and RNA could be delivered
directly to the recipient cells. As a natural cell product, they can avoid
the phagocytosis or degradation of recipient macrophages and in vivo
lysosome degradation, making it possible to circulate in vivo for ex-
tended periods [38, 39]. In addition, EVs can penetrate the blood-brain
barrierwhich is difﬁcult formany drugs to penetrate [40, 41]. Therefore,
stem cells-derived EVs could be isolated in vitro and delivered to the re-
cipient for disease treatment [7, 42–46].
In recent years, many researchers have applied stem cells-derived
EVs to treat liver diseases. Hirata et al. utilized a conditioned medium
of dental pulp stem cells to treatmicewith liver ﬁbrosis, and discovered
that it could inhibit the expression of the inﬂammatory mediator,
induce the apoptosis of activated hepatic stellate cells and play positive
roles in the treatment of liver ﬁbrosis [47]. The study of Tan et al.
revealed that the EVs ofmesenchymal stem cells can promote the hepa-
tocellular regeneration of CCL4-induced liverﬁbrosis inmice and reduce
hepatocellular apoptosis through activating the IL-6/STAT3 pathway.
The manifestations included the high expression of the proliferating
cell nuclear antigen (PCNA), cell cycle protein D1, anti-apoptosis gene
Bcl-xL, and signal transduction and transcriptional activation factor 3
(STAT3) [24]. In addition, stem cell-derived EVs have protective effects
on lipopolysaccharide (LPS), thioacetamide and radiation-induced
acute liver injuries. Stem cell-derived EV transplantation may become
a new treatment method for various kinds of acute liver injuries
[4, 48–53].
Our research group validated the efﬁcacy of hASCs-derived EVs in
rat models of ALF induced by D-gal. The rats in the high-
concentration and low-concentration hASCs-derived EVs groups had
signiﬁcantly higher 72-hour survival rates (100% and 62.5% respec-
tively) than those in the PBS control group (27.3%). It is worth noting
that there was no signiﬁcant difference between the high-
concentration and low-concentration lysate groups and the control
group, which further shows that the hASCs exerted effects mainly
through the EVs they released rather than through the hASCs them-
selves. To explore the mechanism for treating ALF using hASCs-
derived EVs, we carried out RNA sequencing on post-transplantation
rats' liver tissues and found an up-regulation of genes related to the
coagulation function and drug metabolism pathways of the rats in
the high concentration hASCs-derived EVs group. Therefore, we as-
sumed that hASCs-derived EVs transplantation improved the in vivo
status of the coagulation hypofunction of ALF rats and accelerated
the D-gal metabolism process. Moreover, there was a down-
regulation of genes related to signal pathways, which echoed the re-
sults obtained in our ALF rat models induced by D-gal + LPS. This in-
dicates that hASCs-derived EVs could effectively inhibit the expression
of inﬂammatory mediators.
In addition, there was an up-regulation in the human-derived long-
chain non-coding RNA (lncRNA) H19 gene measured in the rats' livers
in the hASCs-derived EVs group. We used software to predict the
microRNA that might interact with human lncRNA H19, and found
that lncRNA H19 happened to be closely associated with the microRNA
of coagulation functions, drug metabolism, etc. pathways. In the previ-
ous RNA sequencing results, we also found an up-regulation in genes
related to the coagulation function and drug metabolic pathways in
rats' livers. As such, we assumed that human hASCs-derived EVs
inhibited the expression of microRNA related to the coagulation
function, drug metabolism, etc. pathways in rat liver tissues, thereby
up-regulating such pathways and improving the survival rate of rats
with ALF.
H19 is a non-coded RNA with a known length of 2.3 kb, its expres-
sion in the liver is active but decreases rapidly after the birth of an indi-
vidual. Youhei et al. detected the expression of theH19 gene in different
time segments in liver regenerationmodels inwhichmost of the rat and
mouse livers were resected, and found that H19 expression increased
signiﬁcantly in tissues with active hepatocellular proliferation; appar-
ently, H19 plays an indispensable role in the regeneration of liver tissues
and the initiation of proliferation [54, 55]. Our research group indicated
that among the rats receiving injections of hASCs-derived EVs via the
iliac vein, those receiving hASCs-derived EVs, hASCs-derived EVs with
the H19 gene silenced and PBS had 72-hour overall survival rates of
100%, 40% and 10% respectively; the rats in the hASCs-derived EVs
group and the hASCs-derived EVs with silenced H19 gene group pre-
sented signiﬁcant differences in terms of the survival rates at different
time points, indicating that lncRNA H19 could improve the survival
rate of rats through hepatocellular proliferation. The in vitro Cell
Counting Kit-8 (CCK8) test also validated that H19-silencing EVs de-
rived from hASCs could reduce the proliferation promotion effects on
human hepatocytes.
To verify the effectiveness of the EVs in a more severe and fatal ALF
model, we adopted a more severe model of inﬂammation induced by
D-gal + LPS and found that the rats in the hASCs-derived EVs group
had a signiﬁcantly higher 72-hour survival rate (50%) than those in
the PBS control group (9%). To observe the inﬂammatory status in
the rats' livers, we used the protein chip method to detect the inﬂam-
matory factors and chemokines in the rat serum. The hASCs-derived
EVs transplantation group had a lower level of such inﬂammatory fac-
tors as IL-1ra, IL-1α, IL-1β, IL-6 and IL-17 than those in the PBS control
group, as well as a lower level of such chemotactic factors as CCL20,
CINC-1, CINC-2α/β, CINC-3, CNTF, CX3CL1, CXCL7, CXCL9, CXCL10
and LECAM-1 than those in the PBS control group. Our results indi-
cated that hASCs-derived EVs can simultaneously down-regulate the
expression of inﬂammatory mediators and chemotactic factors, relieve
the degree of liver tissue necrosis and further improve the survival
rate of ALF rats.
From the RNA sequencing analysis above, we also found an
up-regulation of HGF/c-Met pathway and this was veriﬁed in the
liver tissue of rats using RT-qPCR method. HGF/c-Met pathway is a
well-known pathway associated to cells proliferation. To clearly
know whether lncRNA H19 promotes hepatocyte regeneration via
the HGF/c-Met pathway, we used AAV with an overexpression of
lncRNA H19 to infect hASCs and subsequently collected its EVs. It
was discovered that, whether in vitro or in vivo, the use of EVs
with an overexpression of H19 can further enhance the promotion
role of EVs in hepatocytes' proliferation and restrain hepatocyte apo-
ptosis, and the HGF/c-Met pathway and such related downstream
pathways as PI3K/AKT and STAT3 were all up-regulated, which
hints that H19 can further enhance the role of hASCs-derived EVs
in promoting hepatocytes' proliferation. Then the c-met inhibitor —
AZD6094 was used to block HGF/c-Met pathway in hepatocytes.
After pretreatment with AZD6094, hASCs-derived EVs lost their effect
on promoting hepatocytes' proliferation, the rats' survival rate was
reduced and the experiments in vivo and vitro all indicate that the
EVs had a reduced role in promoting hepatocytes' proliferation and
protecting apoptotic hepatocytes, and the expression of the HGF/c-
Met channel and such related downstream channels as PI3K/AKT
and STAT3 were down-regulated, which indicated that hASCs-
derived EVs may promote hepatocytes' proliferation through the
HGF/c-Met pathway and related downstream channels, thereby in-
creasing the survival rate of rats with ALF.
Up to now, stem cells-derived EVs have increasingly attracted atten-
tions from researchers due to the promising therapeutic effects in ani-
mal models with a variety of diseases. Undoubtedly, there is still much
work to be done before those goals could be achieved, such as the estab-
lishment of the criteria to differentiate between different kinds of EVs,
uniﬁcation of the methodologies for exosome collection, the appropri-
ate concentration and dosage for different conditions, the active ingre-
dients and mechanism of exosome, and more importantly, the long-
term efﬁcacy and clinical safety.
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5. Conclusions
In summary, hASCs-derived EVs show potential therapeutic rele-
vance in acute liver failure animal models. Our research group validated
the efﬁcacy of hASCs-derived EVs in acute liver failure and explored the
role of lncRNAH19 through acute liver failure ratmodels induced by dif-
ferent drugs; the direct use of stem cells-derived EVs instead of the stem
cells themselves is very likely to become a new method with potential
for treating such liver diseases as liver ﬁbrosis and acute liver failure.
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